Results 11 to 20 of about 63,989 (248)

The discovery of rivaroxaban: translating preclinical assessments into clinical practice [PDF]

Frontiers in Pharmacology, 2013
Direct oral anticoagulants that target a single coagulation factor (such as factor Xa or thrombin) have been developed in recent years in an attempt to address some of the limitations of traditional anticoagulants.
Dagmar eKubitza, Elisabeth ePerzborn, Scott D Berkowitz   +2 more
doaj   +3 more sources

Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation.

New England Journal of Medicine, 2022
BACKGROUND Testing of factor Xa inhibitors for the prevention of cardiovascular events in patients with rheumatic heart disease-associated atrial fibrillation has been limited.
S. Connolly, G. Karthikeyan, M. Ntsekhe, A. Haileamlak, Ahmed El Sayed, A. El Ghamrawy, A. Damasceno, Á. Avezum, A. Dans, B. Gitura, D. Hu, Emmanuel R Kamanzi, F. Maklady, G. Fana, J. González-Hermosillo, J. Musuku, K. Kazmi, L. Zühlke, Lillian Gondwe, Changsheng Ma, M. Paniagua, O. Ogah, O. J. Molefe-Baikai, P. Lwabi, P. Chillo, Sanjib K Sharma, T. T. Cabral, W. Tarhuni, A. Benz, Martin van Eikels, A. Krol, Divya Pattath, K. Balasubramanian, S. Rangarajan, C. Ramasundarahettige, B. Mayosi, S. Yusuf   +36 more
semanticscholar   +1 more source

Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial

The Lancet, 2021
Background Patients hospitalised with COVID-19 are at risk for thrombotic events after discharge; the role of extended thromboprophylaxis in this population is unknown.
E. Ramacciotti, Leandro Barile Agati, D. Calderaro, V. C. Aguiar, A. Spyropoulos, C. C. D. de Oliveira, Jessica Lins dos Santos, G. Volpiani, M. L. Sobreira, E. Joviliano, Milton Sérgio Bohatch Júnior, B. D. da Fonseca, M. Ribeiro, C. Dusilek, Kengi Itinose, Suzanna Maria Viana Sanches, Karine de Almeida Araujo Ramos, N. D. de Moraes, P. Tierno, André Luiz Malavasi Longo de Oliveira, A. Tachibana, R. Chate, M. V. B. Santos, Bruno Bezerra de Menezes Cavalcante, R. C. Moreira, C. Chang, A. Tafur, J. Fareed, R. Lopes, Tania Breno Marcello Igor Ivan Liane Lucas Carlos Ana Re Benevenuto Caltabiano Hattori da Silva Jardim Mari, Tania Benevenuto Caltabiano, B. Hattori, Marcello da Silva Jardim, Igor Marinho, Ivan Silva Marinho, Liane Mara Melo Batista, Lucas Rivabem, Carlos Alberto Kenji Nakashima, Ana Carla Gois Franco, Renata Fernanda de Oliveira Pereira, Giana Caroline Strack Neves, Izara de Castro e Souza, Bruno Moraes Ribas, Flavia Ramos Tristão, Marcus Vinicius Barbosa Santos   +44 more
semanticscholar   +1 more source

Study of Rivaroxaban for Cerebral Venous Thrombosis: A Randomized Controlled Feasibility Trial Comparing Anticoagulation With Rivaroxaban to Standard-of-Care in Symptomatic Cerebral Venous Thrombosis

Stroke, 2023
BACKGROUND: Emerging data suggest that direct oral anticoagulants may be a suitable choice for anticoagulation for cerebral venous thrombosis (CVT). However, conducting high-quality trials in CVT is challenging as it is a rare disease with low rates of ...
Thalia Shoshana Field, Vanessa Dizonno, M. Almekhlafi, F. Bala, Ibrahim Alhabli, Hubert Wong, M. Norena, Maria Karina Villaluna, P. King-Azote, Namali Ratnaweera, Steven Mancini, Stephen C Van Gaal, Laura K. Wilson, Brett R Graham, Luciano A. Sposato, D. Blacquiere, B. Dewar, M. Boulos, B. Buck, C. Odier, K. Perera, A. Pikula, Aleksander Tkach, G. Medvedev, Carolyn Canfield, W. Mortenson, Janel O. Nadeau, S. Alshimemeri, Oscar R. Benavente, A. Demchuk, D. Dowlatshahi, S. Lanthier, Agnes Y Y Lee, J. Mandzia, D. Suryanarayan, J. Weitz, Michael D. Hill   +36 more
semanticscholar   +1 more source

Effects of Rivaroxaban on Biomarkers of Coagulation and Inflammation: A Post Hoc Analysis of the X-VeRT Trial. [PDF]

, 2020
Introduction  This X-VeRT (eXplore the efficacy and safety of once-daily oral riVaroxaban for the prevention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion) substudy evaluated the effects of ...
Camm, AJ, Cappato, R, Ezekowitz, MD, Hohnloser, SH, Kirchhof, P, Meng, IL, Purmah, Y, Schiffer, S, Schulz, A, Wosnitza, M   +9 more
core   +1 more source

Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban. [PDF]

, 2020
Background Reducing major bleeding events is a challenge when managing anticoagulation in patients with atrial fibrillation. This study evaluated the impact of modifiable and nonmodifiable bleeding risk factors in patients with atrial fibrillation ...
Amarenco, P, Camm, AJ, Haas, S, Hess, S, Kirchhof, P, Lambelet, M, Turpie, AGG, van Eickels, M, XANTUS Investigators*   +8 more
core   +2 more sources

No relevant pharmacokinetic interaction between the KRAS G12C inhibitor sotorasib and the direct oral anticoagulant rivaroxaban in healthy subjects. [PDF]

Int J Cancer
What's new? Venous thromboembolism (VTE) is common in cancer patients, with direct oral anticoagulants, including rivaroxaban, recommended as first‐line therapy. However, oral anticoagulant use is limited due to the growing use of targeted therapy and concerns about drug‐drug interactions.
Hollander EM, Buma AIG, Leentjens J, Janssen PKC, van den Heuvel MM, Burger DM, Piet B, Ter Heine R.   +7 more
europepmc   +2 more sources

The impact of ABCB1, CYP3A4/5 and ABCG2 gene polymorphisms on rivaroxaban trough concentrations and bleeding events in patients with non-valvular atrial fibrillation

Human Genomics, 2023
Background The influence of genetic factors on the pharmacokinetics and clinical outcomes of rivaroxaban in patients with non-valvular atrial fibrillation (NVAF) is poorly understood.
Tingting Wu, Shuyi Wu, Li Li, Jing Xiang, Na Wang, Wenjun Chen, Jin-hua Zhang   +6 more
semanticscholar   +1 more source

Rationale and design of "Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)" study : A randomised trial modulating endogenous fibrinolysis in patients with acute coronary syndrome [PDF]

, 2019
© The Author(s) 2019. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the ...
Gorog, Diana A, Gue, Ying X, Kanji, Rahim, Srinivasan, Manivannan, Wellsted, David M, Wyatt, Solange   +5 more
core   +2 more sources

Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation.

Journal of the American Medical Association (JAMA), 2021
Importance The comparative effectiveness of rivaroxaban and apixaban, the most frequently prescribed oral anticoagulants for ischemic stroke prevention in patients with atrial fibrillation, is uncertain.
W. Ray, C. Chung, C. Stein, W. Smalley, E. Zimmerman, W. Dupont, A. Hung, J. Daugherty, A. Dickson, K. Murray   +9 more
semanticscholar   +1 more source